17 February 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.
6 December 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its interim results for the six months ended 30 September 2019.
To log on to view a recording of the analyst presentation webcast please click here…
To view the Interim Results Presentation slide deck please click here…
Sharon Grimster (ReNeuron) to be recognised at bioProcessUK conference
13 November 2019: Sharon Grimster of ReNeuron will be awarded the prestigious Peter Dunnill award at the UK BioIndustry Association’s (BIA) 16th bioProcessUK conference in Liverpool later this month.
To view the UK BioIndustry Association’s (BIA) press release please CLICK HERE.
New data show ReNeuron’s lead CTX cell therapy candidate can be
re-programmed into a pluripotent state and differentiated into other cell types
These new cell types can be efficiently expanded as potential cell therapy candidates targeting a broad range of diseases
23 October 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Barcelona, Spain.
Study investigator presents positive efficacy data in ongoing retinal disease clinical trial
14 October 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that positive efficacy data were presented during the weekend at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco from the Company’s Phase 1/2a clinical trial of its hRPC stem cell therapy in retinitis pigmentosa (RP).
To view the presentation please CLICK HERE.
“Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa
02 October 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce new positive data in the Company’s ongoing Phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).
12 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting (“AGM”) held earlier today were duly passed.
10 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of the Company’s Annual General Meeting (“AGM”) this Thursday.
21 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces the appointment of Professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its Scientific Advisory Board.
14 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is partnering with the University of Cardiff under a new grant-funded collaboration utilising ReNeuron’s exosome-based drug delivery technology platform.
For our archived news, click here
